Sunday, 4 October 2026European Markets

Everyone plans to deploy AI agents, but the data may not be ready: what the evidence holds up, and where Europe fits

A survey says every organisation will use agentic AI within two years, with company data as the bottleneck. That survey source scores 0% on our reliability check, so we treat it as a claim to test. Verified Nvidia filings and named company deals give firmer ground. Europe's role in this material is thin, and we say so.

LM Salvado
LM Salvado

October 4, 2026

Everyone plans to deploy AI agents, but the data may not be ready: what the evidence holds up, and where Europe fits
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Reading time is short on purpose: the European angle in this material is thinner than the headline topic suggests, and we would rather say so than stretch it. Three things in the record are named and checkable. They are a Canadian insurer's five-year deal with Microsoft, a set of agent-security controls from Box, and a run of Nvidia financial filings. The headline survey numbers are the weakest part of the picture, and we start there.

The headline survey: a strong claim from a weak-scoring source

A report titled "Scaling AI agents with trustworthy data" states that within two years 100% of respondents plan to be using agentic AI, with 69% expecting to use it widely.1 The same report says that in organisations it classes as 'data laggards', AI access to company data falls to 30% or less.1 The topic summary we were given adds that only about 45% of company data is AI-accessible on average and that about half of organisations trust their agents' decisions. We do not hold a verbatim passage for those two figures, so treat them as reported, not confirmed.

Here is the seam. Our measured reliability check on this source found that 0% of the 11 claims we checked held up.1 That does not prove the numbers are wrong. It means we could not confirm them, and a figure like "100% of respondents" should make any reader ask who was surveyed. The dossier does not say, and we will not guess.

The central idea is still reasonable: an AI agent can only be as useful as the data it can reach and trust. We cannot tell you how large the gap is.

The European angle: little here, and what there is

The dossier contains no EU regulation, no EU company with a verified fact attached, and no European market data. The summary mentions Siemens and Nvidia deepening ties, but we hold no detail on that partnership, so we make no claim about it. David Villalon of Maisa AI defines his market as process automation of core business and production tasks at regulated industries, covering back office, operations and finance, work that must be auditable, reproducible and hallucination resistant.2 That is a description of what regulated customers demand. It is not evidence about Europe, and the dossier does not place Maisa in any country.

Covecta, a banking-focused AI company, says it serves corporate and commercial banks, specialist non-bank lenders, building societies, credit unions and private credit firms, currently across the US and the UK, with aspirations to move globally.3 The UK is outside the EU, and no EU country appears in that list. For a European reader the fair reading is that this vertical AI wave is, on this evidence, still aimed elsewhere.

Big companies are buying governance, not just models

The most concrete deal in the record is Manulife and Microsoft. The two announced on 22 July 2026 a renewal and expansion of their relationship. It is a five-year agreement. Manulife will adopt Microsoft's Frontier Suite, deploy Microsoft Agent 365, and expand Microsoft 365 Copilot to more than 30,000 employees.4 Shamus Weiland said: "Our partnership with Microsoft is a critical enabler of Manulife's continued evolution into a truly AI-driven organization."4 The release is titled as a push for AI governance as well as innovation. Note that this is a company press release, so the framing is Manulife's and Microsoft's own.

Box made a similar point on 21 July 2026. It announced agent guardrails, oversight of third-party agent activity, prompt injection detection and access policies based on agent classification.5 Tatsutoshi Murata of Nomura Research Institute said the firm expects Box to provide the administrative features needed to safely leverage AI agents.5 He also said it values Box's multi-vendor support, which lets it switch between AI models.5 Both sources carry a measured reliability score: 57% of 4,954 checked claims from this news feed held up.4,5 That is better than a coin flip, but not enough to take a press release at face value without a second source.

Our reading, which is Via News's analysis and not a sourced fact: the money in these two announcements goes to control, meaning who can see what an agent does and how it is kept in bounds. That fits the data-trust bottleneck above. We cannot show from this dossier that one caused the other.

The money in the substrate: what Nvidia's filings show

Nvidia supplies the hardware layer for much of this. Its filings give us checked numbers, though the dossier carries cash and cost figures but no revenue, so this is a partial picture.

Quarterly cash rose from $5.079 billion in Q1 20246 to $15.234 billion in Q1 2026,7 roughly triple, before easing to $13.237 billion in Q1 2027.8 Annual cost of revenue, the direct cost of producing what Nvidia sells, went from $16.621 billion in FY 20249 to $32.639 billion in FY 202510 and $62.475 billion in FY 2026.11 That is about 3.8 times in two years. A cost line rising that fast generally means a business selling far more, but cost alone does not tell us profit.

Earnings per share are harder to read. They were $11.93 in FY 2024,12 $2.94 in FY 202513 and $4.90 in FY 2026.14 The dossier does not explain the drop between the first two years, so do not compare these three figures as like for like until the share count is checked. We will not guess at the cause.

If you hold a broad index fund, you may own Nvidia indirectly. The dossier gives no weighting, so we cannot say how much.

The entity graph links Nvidia to named customers, including Mount Sinai Health System, the State of Alaska Legislative Affairs Agency and Yum! Brands. It also lists agent-related Nvidia products such as NeMo Guardrails and NeMo Agent Toolkit, and names AMD as a competitor. These are relationships, not revenue figures.

Start-ups are pricing themselves against labour, not software

The vertical players size their markets by what customers spend on people. Ben Thomas of Covecta says its market is tens of thousands of financial institutions, and that "we are not just disrupting their software budget but their labor budget as well."3 Glenn Herzberg of Penguin AI says US healthcare administration runs about a trillion dollars a year, about a quarter of total health spend, and that published estimates put around $570 billion of it in work with no effect on health outcomes.15 That is Penguin's own framing and an estimate it attributes to published sources, not a figure we verified.

The pitch is that automating administrative work is a larger prize than selling software. It also means the buyer's staff are the target. For European firms with strong labour protections, that is a question the dossier does not touch.

Money is also moving. Latitude, a payments platform founded by ex-Stripe crypto team member Cyril Mathew, raised a $35 million Series A on 10 September 2026 for a stablecoin-to-local-currency payments platform.16 CB Insights published a run of founder interviews in late September from Shepherd, Arlo, LARX, Veridox and Binary World, all as part of its enterprise AI coverage.17 Those are interviews, not funding or revenue evidence.

The chips keep coming

The infrastructure build-out is scheduled well ahead. Alibaba's T-Head Zhenwu V900 AI chip is set for commercial release in Q3 2027, and the J900 in Q3 2028.18 Those are scheduled dates, not deliveries, and the dossier gives no performance specifications.

What to watch

  • The survey's method. Until the 100% and 45% figures can be traced to a sample, treat them as unconfirmed.
  • Any European deployment of the governance tools above. That would be the first real European evidence in this story.
  • Nvidia's cash and cost lines. Cash eased between Q1 2026 and Q1 2027 while costs climbed, and we hold no revenue to put against them.
  • The 2027 and 2028 chip dates. Slippage would be the signal.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· July 21, 2026
    Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content
  2. [2]News articleCB Insights
    CEO Interview: David Villalon, Maisa
  3. [3]News articleCB Insights
    Executive Interview: Covecta
  4. [4]News articleCB Insights
    Executive Interview: Penguin AI
  5. [5]News articleCB Insights
    Investor Interview: Primary on Casap
  6. [6]News articleYahoo Finance· July 22, 2026
    Manulife Expands Partnership with Microsoft to Accelerate Enterprise AI Governance and Innovation
  7. [7]News articleMIT Technology Review
    Scaling AI agents with trustworthy data
  8. [8]News articleMotley Fool
    C3.ai CEO Thomas Siebel Sells 453,000 Shares for $4.8 Million
  9. [9]News articleCB Insights
    CEO Interview: Arlo
  10. [10]News articleCB Insights
    CEO Interview: Binary World
  11. [11]News articleCB Insights
    CEO Interview: LARX
  12. [12]News articleCB Insights
    CEO Interview: Shepherd
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com